178 related articles for article (PubMed ID: 24111178)
41. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats T
Eur J Pharmacol; 2009 Jan; 602(2-3):188-93. PubMed ID: 19027730
[TBL] [Abstract][Full Text] [Related]
42. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
43. Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells.
Arcella A; Palchetti S; Digiacomo L; Pozzi D; Capriotti AL; Frati L; Oliva MA; Tsaouli G; Rota R; Screpanti I; Mahmoudi M; Caracciolo G
ACS Chem Neurosci; 2018 Dec; 9(12):3166-3174. PubMed ID: 30015470
[TBL] [Abstract][Full Text] [Related]
44. A Combined Approach Employing Chlorotoxin-Nanovectors and Low Dose Radiation To Reach Infiltrating Tumor Niches in Glioblastoma.
Tamborini M; Locatelli E; Rasile M; Monaco I; Rodighiero S; Corradini I; Franchini MC; Passoni L; Matteoli M
ACS Nano; 2016 Feb; 10(2):2509-20. PubMed ID: 26745323
[TBL] [Abstract][Full Text] [Related]
45. Characteristics of sequential targeting of brain glioma for transferrin-modified cisplatin liposome.
Lv Q; Li LM; Han M; Tang XJ; Yao JN; Ying XY; Li FZ; Gao JQ
Int J Pharm; 2013 Feb; 444(1-2):1-9. PubMed ID: 23347891
[TBL] [Abstract][Full Text] [Related]
46. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
[TBL] [Abstract][Full Text] [Related]
47. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
Kim SS; Harford JB; Pirollo KF; Chang EH
Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
[TBL] [Abstract][Full Text] [Related]
48. M-MDSCs mediated trans-BBB drug delivery for suppression of glioblastoma recurrence post-standard treatment.
Yu T; Wang K; Wang J; Liu Y; Meng T; Hu F; Yuan H
J Control Release; 2024 May; 369():199-214. PubMed ID: 38537717
[TBL] [Abstract][Full Text] [Related]
49. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
[TBL] [Abstract][Full Text] [Related]
50. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
51. Enhancement in blood-tumor barrier permeability and delivery of liposomal doxorubicin using focused ultrasound and microbubbles: evaluation during tumor progression in a rat glioma model.
Aryal M; Park J; Vykhodtseva N; Zhang YZ; McDannold N
Phys Med Biol; 2015 Mar; 60(6):2511-27. PubMed ID: 25746014
[TBL] [Abstract][Full Text] [Related]
52. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
53. Harnessing nanomedicine for therapeutic intervention in glioblastoma.
Gutkin A; Cohen ZR; Peer D
Expert Opin Drug Deliv; 2016 Nov; 13(11):1573-1582. PubMed ID: 27292970
[TBL] [Abstract][Full Text] [Related]
54. Low renal toxicity of lipoplatin compared to cisplatin in animals.
Devarajan P; Tarabishi R; Mishra J; Ma Q; Kourvetaris A; Vougiouka M; Boulikas T
Anticancer Res; 2004; 24(4):2193-200. PubMed ID: 15330160
[TBL] [Abstract][Full Text] [Related]
55. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells.
Kato T; Natsume A; Toda H; Iwamizu H; Sugita T; Hachisu R; Watanabe R; Yuki K; Motomura K; Bankiewicz K; Wakabayashi T
Gene Ther; 2010 Nov; 17(11):1363-71. PubMed ID: 20520650
[TBL] [Abstract][Full Text] [Related]
56. Local immunotherapy (beta-IFN) and systemic chemotherapy in primary glial tumors.
Boiardi A; Silvani A; Milanesi I; Munari L; Broggi G; Botturi M
Ital J Neurol Sci; 1991 Apr; 12(2):163-8. PubMed ID: 1649148
[TBL] [Abstract][Full Text] [Related]
57. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts.
Boulikas T
Oncol Rep; 2004 Jul; 12(1):3-12. PubMed ID: 15201951
[TBL] [Abstract][Full Text] [Related]
58. The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.
Hosein AN; Lim YC; Day B; Stringer B; Rose S; Head R; Cosgrove L; Sminia P; Fay M; Martin JH
J Neurooncol; 2015 Apr; 122(2):263-71. PubMed ID: 25648357
[TBL] [Abstract][Full Text] [Related]
59. Nanoparticles: Novel vehicles in treatment of Glioblastoma.
Pourgholi F; Hajivalili M; Farhad JN; Kafil HS; Yousefi M
Biomed Pharmacother; 2016 Feb; 77():98-107. PubMed ID: 26796272
[TBL] [Abstract][Full Text] [Related]
60. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
